isb_pp_eng1.jpg

The contemporary science about drugs consists of two main disciplines - pharmacology and pharmaceutics. The first is responsible for research of medico-biological properties of drugs, the second – for their chemical structure and production techniques investigations. Researches are curried out in one and another directions.

Pharmacological studies could be justly considered as one of the priority directions. It is possible to say that in this sphere we touched on the main tasks of this discipline, i.e. we study drug discovery and drug side effects problems. Also we develop drug safety methods and analyze clinical trials data.

During our life we have taken a great amount of drugs and bioactive compounds, however far from everyone think about that, besides perceptible benefit, they do irreparable damage to the our organisms. For example, taking widely known aspirin and others salicylates (the matter concerns recommended curative dose, not an overdose) could have pernicious effect on the state of blood and liver. Strange as it may seem, scientists started detailed research of drug side effects comparatively recently and by our sight not in an optimal volume. We should add that Kinetic Modeling have at this point the number of significant advantages in comparison with others methods of Systems Biology.

Everything said above concerns also the problem of drug safety, i.e. development of such methods of drug using when the variety of their side effects decreases maximally with keeping of positive medical action. We are focusing our attention on the research in this field of pharmacology as well; that confirms the received results.

Model approach, which is developed in the ISBSPb, allows to increase an eficacy of processing and analysis data of the different stages of clinical trials. In the competitive pharmaceutical and biotech landscape, the market success of any new product depends on how well a company executes a clinical development program. Success depends on integrating scientific and clinical data to the development and commercialization of therapies. Exactly for this we have developed in the ISBSPb several innovative techniques for these tasks.



Model-based Drug Development Examples

The development of a new drug is a high risk and costly activity that involves multiple decisions and tradeoffs. Model-Based Drug Development Approach (MBDDA) allows combining proprietary data on a specific compound with literature data of its likely competitors and, thereby, represents powerful tool for managing risks concerning dose selection, efficient and effective trial design, and "go/no-go" decisions. MBDDA enables us to combine whole organism description specified by PBPK model, peculiarities of drug distribution and delivery given by systemic model, detailed description of inter- and intra- cellular processes assigned by kinetic model and quantitative dose-effect relationship preset by PK/PD model.

mbdd_deseases_eng

Read more...

 
Research of aspirin and others salicylates side effects on the energetic metabolism

thumb_aspirin_1The lesion of liver is one of the most serious side effects which arise after using of aspirin. Negative influence on hepatocytes shows not only in case of overdose but also in curative doses which are prescribed for curing of several diseases (for example arthritis). One of the reasons of that is abnormality in regulation and functioning of the energetic metabolism of liver cells, particularly, Krebs cycle. Investigation of drug side effects mechanisms consists in two parts. Firstly, it is necessary to understand how is possible to decrease toxic effects of existed drugs. Secondly – to prognose new drug side effects that may significantly decrease production inputs and – in main - risk of their using. The strategy of complex research drugs action and their side effects was developed for that in our laboratory on the basis of kinetic modeling. AAs an example of this method using for drug side effects research we investigated the mechanisms of action of aspirin and other salicylates on the work of mitochondrion in liver cells, in particular, on the Krebs cycle.

Read more...
 
Development of model based screening algorithm for identification of potential antipheumonia drugs

thumb_Antipheumonia_1_ruOne of the first steps during new drugs development is known to be the screening of library of potential compounds. The method of this procedure optimization was developed in our laboratory. This method represents development of kinetic model of concerned biochemical systems, finding of all available quantitative experimental data, which characterizing their functioning and regulation, and taking all these data into model account. Such approach allows not only collect together all the information available about the concerned biochemical system, but also use it effectively on the pre-clinical stages of new drugs development, in particular, during the search of protein target and effective clinical candidates optimization. The method of information processing, given in the framework of this approach, allows finding effective inhibitors not only for one protein target but also in that case when biotarget is represented by the part of metabolic or signal way.

The method was successfully used for optimization of library compounds screening procedure and during creation of the new antipheumonia drug, which effectively influencing the viability Streptococcus pneumonia.

Read more...
 
<< Start < Prev 1 2 3 Next > End >>

Page 1 of 3

Download

Select language

RussianEnglish

Contacts

Institute for Systems Biology SPb

Moscow, Leninskie Gory, 1, build.75G, office. 613, Science park, 119992

+7(495)930-8407,   +7(495)930-8407, +7(495)783-8718

insysbio@insysbio.ru   insysbio@insysbio.ru

Search